482 related articles for article (PubMed ID: 30130439)
1. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
2. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
Kiessling P; Lledo-Garcia R; Watanabe S; Langdon G; Tran D; Bari M; Christodoulou L; Jones E; Price G; Smith B; Brennan F; White I; Jolles S
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093180
[TBL] [Abstract][Full Text] [Related]
3. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells
Qureshi OS; Sutton EJ; Bithell RF; West SM; Cutler RM; McCluskey G; Craggs G; Maroof A; Barnes NM; Humphreys DP; Rapecki S; Smith BJ; Shock A
MAbs; 2024; 16(1):2300155. PubMed ID: 38241085
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
Lledo-Garcia R; Dixon K; Shock A; Oliver R
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):116-128. PubMed ID: 34735735
[TBL] [Abstract][Full Text] [Related]
5. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
6. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
Ng CM; Fielder PJ; Jin J; Deng R
AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Robak T; Kaźmierczak M; Jarque I; Musteata V; Treliński J; Cooper N; Kiessling P; Massow U; Woltering F; Snipes R; Ke J; Langdon G; Bussel JB; Jolles S
Blood Adv; 2020 Sep; 4(17):4136-4146. PubMed ID: 32886753
[TBL] [Abstract][Full Text] [Related]
11. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
[TBL] [Abstract][Full Text] [Related]
12. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis.
Matic A; Alfaidi N; Bril V
Expert Opin Biol Ther; 2023; 23(12):1163-1171. PubMed ID: 38099334
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
15. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR
Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500
[TBL] [Abstract][Full Text] [Related]
16. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.
Mezo AR; McDonnell KA; Hehir CA; Low SC; Palombella VJ; Stattel JM; Kamphaus GD; Fraley C; Zhang Y; Dumont JA; Bitonti AJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2337-42. PubMed ID: 18272495
[TBL] [Abstract][Full Text] [Related]
17. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
Li J; Wu X; Chu T; Tan X; Wang S; Qu R; Chen Z; Wang Z
J Neurol; 2024 May; 271(5):2298-2308. PubMed ID: 38431900
[TBL] [Abstract][Full Text] [Related]
19. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
[TBL] [Abstract][Full Text] [Related]
20. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
